Janssen&Janssen schreef op 7 september 2021 20:21:
klein voorbeeld wbt technische potentie, artikel is al van 2005
www.jimmunol.org/content/174/10/6462C1INH replacement therapy for acute attacks of angioedema has been used in patients with hereditary angioedema for >25 years. Surprisingly, treatment with C1INH is beneficial in a variety of other disease models, including sepsis, brain, and myocardial ischemia-reperfusion injury, hyperacute transplant rejection, traumatic shock, and the vascular leak syndromes associated with thermal injury, IL-2 therapy, and cardiopulmonary bypass (3). The mechanism underlying these beneficial therapeutic effects has been explained primarily as a result of the inhibition of the complement and contact systems. Such inhibition would, therefore, result in a reduction in the generation of the biologically active end products of these systems, such as the anaphylatoxins C3a and C5a, the C5b-9 membrane attack complex, and bradykinin, all of which can induce tissue injury